Special Issue "Clinical Applications of Molecular Subtyping of Pancreatic Cancer"
Deadline for manuscript submissions: 1 July 2024 | Viewed by 59
Pancreatic cancer is one of the biggest oncological and surgical challenges, for pancreatic malignancies are the fourth leading cause of death in adults and cause an estimated loss of 600,000–915,000 quality-adjusted life years (QALYs). Aggressive tumor growth and late diagnosis are primarily responsible for unfavorable prognosis, and although survival rate has improved in recent decades, it continues to remain low for patients with advanced pancreatic disease. With the evolution of genomics, next generation and whole genome sequencing, we now have an opportunity to tackle the aggressive growth and expansion of pancreatic tumors using novel techniques that might enable personalized treatment of pancreatic cancer patients. Utilization of a molecular taxonomy of pancreatic cancer will inform preclinical and clinical decision-making and assist in the development of novel therapeutic interventions.
This Special Issue is dedicated to publishing research centered around the developments in molecular subtyping of pancreatic cancer, whether related to a novel method, a transcriptomic subtype method or single gene alteration. Research on the practical applications of molecular subtyping in clinical practices, such as decision-making in surgical approaches, correlations with postoperative outcomes, administration of chemotherapy and long-term response, are encouraged. Future perspectives of genome-based subtyping will also be considered, especially regarding pancreatic transplantation where in vivo models of pancreatic transplantation have revealed progression and alteration of PDAC molecular subtypes. Therefore, we cordially invite researchers with experience in the MDT approach for the treatment of pancreatic diseases to share their invaluable insights.
In this Special Issue, original research articles, reviews, and expert opinions are welcome. Research areas may include (but are not limited to) the following:
- Implications of pancreatic molecular cancer in pancreatic surgery;
- Association of postoperative outcomes in different molecular subtypes;
- Response to systematic therapy according to molecular subtypes;
- Implications of pancreatic transplant in genomic changes;
- Use of NGS in pancreatic cancer specimens;
- Personalized decision-making based on molecular subtyping;
- New advancements in targeted treatment strategies.
We look forward to receiving your contributions.
Prof. Dr. Ioannis C. Maroulis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pancreatic cancer
- pancreatic adenocarcinoma
- genomic subtyping
- next generation sequencing
- pancreatic surgery
- pancreatic transplantation